U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123727) titled 'A Study to Examine Anktiva for the Treatment of COVID-19.' on July 30.
Brief Summary: This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Long COVID
Long COVID Syndrome
Long Covid 19
Intervention:
DRUG: Anktiva
600ug of NAI administered subcutaneously
Recruitment Status: RECRUITING
Sponsor: ImmunityBio, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....